Biomarkers in pancreatic ductal adenocarcinoma

• J. Gallego ^[5] ; C. López ^[1] ; R. Pazo-Cid ^[2] ; F. López-Ríos ^[3] ; Alfredo Carrato ^[4]
  1. [1] Hospital Universitario Marqués de Valdecilla

     Hospital Universitario Marqués de Valdecilla

     Santander, España

     
  2. [2] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  3. [3] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  4. [4] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  5. [5] Hospital Universitario de Elche

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 12, 2017, págs. 1430-1437
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease. Nomenclature for molecular subtypes of tumours is gradually gaining acceptance and there are growing expectations it will further go from the bench to the bedside. However, the clinical relevance of biomarkers in PDAC is still far behind the relevance of biomarkers in other solid tumours. This article is part of a wider project (GALLgo) involving over forty specialists devoted to the multidisciplinary management of PDAC which concluded in recommendations based on scientific evidence. The aim of the present article is to review the diagnostic, prognostic and predictive biomarkers, either in localised or advanced disease, which have been lately subjected to study and analysis and others currently available for PDAC in order to give strength-graded recommendations linked to quality of evidence that can be used as guidelines in routine clinical practice.